Agios Pharmaceuticals Director Jeffrey Capello Receives 1,976 Shares from RSU Vesting

This Form 4 filing reports that Jeffrey D. Capello, a director of Agios Pharmaceuticals, Inc., received 1,976 shares of common stock on June 13, 2026 through the vesting of restricted stock units (RSUs). The RSUs were originally granted on June 13, 2023 and vested in accordance with their three-year annual installment schedule. The shares were acquired at $0 per share as part of the equity compensation arrangement. Following this transaction, Capello now holds a total of 8,049 shares of Agios Pharmaceuticals common stock. The filing indicates this was a mandatory transaction (code M) where the RSUs were disposed of and converted into common stock. The transaction represents the continued vesting of director compensation previously awarded and demonstrates the ongoing implementation of the company's equity incentive program for board members.